Strong product sales offset a mixed pipeline trial result
- ACADIA has two approved drugs: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
- In Q3 2026, NUPLAZID net sales were $202 million and DAYBUE net sales were $140 million.
- DAYBUE grew 39 percent year over year in the third quarter, helped by the STIX formulation.
- A new US patent protects DAYBUE until 2041, and the drug officially received European Commission approval.
- The ACP-204 Phase 2 trial in Alzheimer's disease psychosis missed its main statistical goal.
- Finn scores point to a decent business with good financial health, but not a cheap stock.
Two growing drugs, one complicated pipeline
ACADIA sells two FDA-approved medicines and uses that cash to fund more CNS drug work. Q3 2026 showed exactly why the commercial setup is interesting. DAYBUE had $140 million of net sales and grew 39 percent year over year, driven by strong early demand for DAYBUE STIX. Management noted that over 50 percent of DAYBUE patients are now using the STIX formulation.
NUPLAZID remains the steadier part of the story. It had $202 million of Q3 2026 net sales, growing 12 percent year over year on an adjusted basis. The franchise is performing reliably as it tracks toward a management target of $1 billion in 2028 sales.
The European question for DAYBUE completely resolved after the European Commission officially approved the drug. This clears the final major regulatory hurdle and sets up the ongoing launch in Germany. Back in the US, a newly allowed patent extends protection for DAYBUE until March 2041.
The main swing factor is ACP-204, also called remlifanserin. Top-line Phase 2 results for Alzheimer's disease psychosis missed statistical significance on the primary endpoint. However, the 60mg dose showed enough activity for management to move forward with a modified Phase 3 trial. This shifts the pipeline narrative from an easy win to a high-stakes, complicated late-stage program.
Sales fund the science
ACADIA makes money by selling prescription drugs. NUPLAZID treats hallucinations and delusions linked to Parkinson's disease psychosis. DAYBUE treats Rett syndrome, a rare brain and development disorder.
This model is healthier than many biotech models because the company is commercial stage, cash-flow positive, and has no debt in the internal view. That means its existing products can help pay for research instead of relying only on new stock sales or borrowing.
The weak point is concentration. All product revenue comes from two medicines. If DAYBUE use slows or ACP-204 fails in Phase 3, the long-term growth story gets thinner fast. Competition in the Rett syndrome space is also heating up.
Valuation also matters. The business is better funded than many biotech peers, but Finn valuation scores are modest. Investors are already paying for part of the good commercial news.
What ACADIA sells and studies
NUPLAZID
NUPLAZID is approved in the U.S. for hallucinations and delusions tied to Parkinson's disease psychosis. It is the mature profit engine, with sales reaching $202 million in Q3 2026.
DAYBUE
DAYBUE is the first FDA-approved treatment for Rett syndrome. Q3 2026 net sales were $140 million, as the new STIX powder form continues to help adoption.
DAYBUE in Europe
DAYBUE officially received European Commission approval in Q3 2026. The initial launch phase is starting in Germany.
ACP-204
ACP-204 is a next-generation 5HT2A compound being tested in Alzheimer's disease psychosis. The Phase 2 RADIANT study missed statistical significance on its primary endpoint, but the company is proceeding to Phase 3 with trial modifications.
ACP-211
ACP-211 is a once-a-day oral compound for major depressive disorder. Phase 2 (NORLIGHT) results are expected in the second half of 2027.
ACP-711
ACP-711 is a potential first-in-class GABA-Alpha-3 positive allosteric modulator for essential tremor. A Phase 2 study is delayed slightly to explore higher dosing, expected to begin in 2027.
ACP-271
ACP-271 is a GPR88 agonist progressing through Phase 1 trials.
Revenue is all product sales
ACADIA reports as one operating segment, but Q3 2026 product sales were split between NUPLAZID and DAYBUE. The mix below uses Q3 2026 net product sales of $202 million for NUPLAZID and $140 million for DAYBUE.
What could break the thesis
ACP-204 Phase 3 trial risk
High impact · High oddsThe pipeline is now heavily tied to ACP-204, but the Phase 2 RADIANT study missed its primary statistical goal. The Phase 3 program will rely on trial design optimizations like central raters to achieve a positive outcome.
Emerging Rett syndrome competitors
High impact · Medium oddsACADIA currently has a monopoly in Rett syndrome, but new treatments are advancing quickly. UCB, Taysha Gene Therapies, and Neurogene all have pivotal trials underway that could eventually erode DAYBUE market share.
DAYBUE STIX persistency issues
High impact · Medium oddsGrowth is increasingly driven by DAYBUE STIX uptake, bringing back discontinued patients. The key question is whether that demand continues or fades over time.
EU commercial execution struggles
Medium impact · Medium oddsWith the European Commission approval secured, the focus shifts to commercial launch. Pricing and reimbursement negotiations, starting in Germany, can slow revenue.
NUPLAZID exclusivity and pricing pressure
Medium impact · Medium oddsNUPLAZID could face Medicare price negotiation as early as 2029, and uncertainty remains around a potential six-month pediatric exclusivity extension.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near ACADIA Pharmaceuticals Inc. in Finn's Biotechnology industry ranking.

